NAD+ and Longevity: Cellular Aging Research

Few molecules have crossed from biochemistry textbooks into mainstream longevity discussion as completely as NAD+ — nicotinamide adenine dinucleotide. It was first isolated in 1906, and for most of the next century it was understood primarily as a “redox cofactor” — a humble electron carrier that allowed mitochondria to extract energy from food. Then, in the early 2000s, a series of discoveries revealed that NAD+ is also the obligatory substrate for an entire class of enzymes that govern aging biology — the sirtuins, the PARPs, and CD38 — and the field changed.

Today, NAD+ is one of the most-researched molecules in cellular aging, with thousands of published papers spanning mitochondrial biology, neurodegeneration, metabolic disease, and stem-cell exhaustion. This article walks through what the peer-reviewed research actually establishes about how NAD+ works, why its levels decline with age, and where the research is heading. It is written for researchers and curious readers; nothing on this page is a recommendation for human use.

What NAD+ Actually Is

Nicotinamide adenine dinucleotide is a small dinucleotide composed of two linked nucleotides — one bearing nicotinamide, the other adenine — connected by phosphate groups. It exists in two interchangeable forms: NAD+ (oxidized) and NADH (reduced). The interconversion between these two states is how cells move electrons during metabolism: glucose, fatty acids, and amino acids are progressively oxidized, and the electrons released get loaded onto NAD+ to form NADH, which is then ferried to the mitochondrial electron transport chain to generate ATP.

That alone made NAD+ essential for life. But beginning with the discovery of the sirtuin family in the late 1990s and 2000s (Imai et al., Nature 2000), researchers established that NAD+ also serves as the substrate that several enzyme families consume to function. Unlike the redox role — where NAD+ is recycled — these enzymes literally cleave NAD+ apart, splitting it into nicotinamide and ADP-ribose during their catalytic cycle. Every time a sirtuin or PARP or CD38 fires, an NAD+ molecule is destroyed. The cell must continuously replace it.

This dual function — recyclable redox cofactor and consumable enzyme substrate — is what makes NAD+ central to aging biology. The supply has to keep up with both demands.

Mechanism Pillar 1: The Sirtuin Pathway

The sirtuins are a family of seven NAD+-dependent enzymes (SIRT1 through SIRT7) that act as cellular sensors of metabolic state. They remove acetyl groups from histones and from hundreds of cytoplasmic and mitochondrial proteins, and in doing so they regulate gene expression, mitochondrial biogenesis, fatty acid oxidation, and stress responses. Activity scales with NAD+ availability: when cellular NAD+ is high (during fasting or caloric restriction), sirtuin activity rises; when NAD+ is low (overfeeding, aging, oxidative stress), sirtuin activity falls.

Imai and Guarente, in their 2014 review in Trends in Cell Biology, summarized two decades of sirtuin research and proposed that age-related decline in NAD+ is one of the upstream drivers of the parallel decline in sirtuin function — and that restoring NAD+ levels in aged tissue can re-activate sirtuin signaling. Subsequent work has reinforced this picture across multiple tissues. Mills and colleagues (2016), in Cell Metabolism, reported that NAD+ restoration via the precursor NMN (nicotinamide mononucleotide) reversed multiple markers of mitochondrial dysfunction in aged mice and partially rescued metabolic phenotypes consistent with restored sirtuin signaling.

Mechanism Pillar 2: PARPs and the DNA-Damage Response

Poly-(ADP-ribose) polymerases — the PARP family — are the second major class of NAD+-consuming enzymes. PARPs activate aggressively in response to DNA damage, attaching long chains of ADP-ribose onto damaged chromatin to recruit repair machinery. Each PARP1 activation event consumes substantial NAD+; under heavy genotoxic stress, PARP can drain cellular NAD+ pools rapidly enough to compromise sirtuin function and even threaten cell viability.

The implication for aging: tissue that accumulates DNA damage — which everything does, with age — runs PARPs harder, depleting the very NAD+ pool that sirtuins need to maintain mitochondrial health and stress resistance. Fang and colleagues (Cell, 2014) characterized this competition explicitly in models of mitochondrial dysfunction, and the result was a positive-feedback loop: damage drives PARP activation, which depletes NAD+, which compromises sirtuin-mediated mitochondrial maintenance, which creates more reactive oxygen species, which causes more damage. NAD+ restoration in this loop has been studied as a candidate research approach for breaking the cycle.

Mechanism Pillar 3: CD38 and the NAD+ “Drain”

CD38 is a third NAD+-consuming enzyme, originally characterized as an immune-cell-surface antigen but now understood to be a major cellular consumer of NAD+ — particularly in aged tissue. Chini and colleagues (Trends in Biochemical Sciences, 2017) reported that CD38 expression rises substantially with age across multiple tissues and that this increase is sufficient to account for a large fraction of the age-related decline in cellular NAD+ levels. CD38 inhibition in aged mice has been shown to restore NAD+ to youthful levels (Camacho-Pereira et al., Cell Metabolism, 2016).

CD38 has become the explanation researchers most often invoke for the question of *why* NAD+ levels decline with age. It is not just that synthesis falls — though it does — but that CD38-mediated consumption rises. The aged cell is leakier and more demanding on its NAD+ supply at the same time.

Mechanism Pillar 4: Mitochondrial Function and DNA Repair

Beyond the three enzyme classes that consume NAD+, the molecule’s fundamental redox role also matters for aging biology. Mitochondria are the largest cellular consumer of NAD+/NADH cycling, and mitochondrial dysfunction is one of the canonical hallmarks of aging (López-Otín et al., Cell, 2013). When NAD+ is scarce, electron transport chain activity slows, ATP production falls, and reactive oxygen species rise — driving the broad metabolic-decline pattern seen in aged tissue.

NAD+ also feeds into the mitochondrial sirtuin SIRT3, which deacetylates and activates dozens of mitochondrial enzymes including superoxide dismutase 2 (the primary mitochondrial antioxidant) and isocitrate dehydrogenase. Verdin’s 2015 Science review brought these threads together into the model that has shaped much of the NAD+ research field since: NAD+ is the metabolic currency that mitochondria use to maintain themselves, and its decline is both a cause and a marker of mitochondrial aging.

Where the Research Is Heading

A handful of large open questions are driving the current NAD+ research frontier. The first is whether NAD+ restoration through the dietary precursors NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) actually translates the impressive rodent results into measurable human outcomes. Several small clinical trials have been published — Yoshino and colleagues (Science, 2021) reported a Phase II study showing that NMN supplementation improved muscle insulin sensitivity in postmenopausal prediabetic women; Brakedal and colleagues (NADPARK trial, Cell Metabolism, 2022) reported that NR raised brain NAD+ levels and produced clinical signal in early-stage Parkinson’s research. Larger Phase III trials are ongoing.

A second question is whether selective inhibition of specific NAD+-consuming enzymes — particularly CD38 — could be a more targeted research approach than blanket NAD+ supplementation. Several preclinical CD38 inhibitors have shown promising results in restoring tissue NAD+ pools in aged mice, and the question of whether these strategies translate to humans is actively being explored.

A third and more philosophical question is whether NAD+ is causally upstream of aging biology, or whether it is a downstream marker. The model implied by Imai, Verdin, Sinclair, and others is causal — restore NAD+, restore function. The contrarian view is that NAD+ decline is a *consequence* of more fundamental aging processes, and that boosting it without addressing the underlying drivers will produce only short-term effects. The next decade of clinical research will probably resolve this question one way or the other.

Researching with Peptide-Grade NAD+

NAD+ is unusually sensitive to source quality. Lyophilized NAD+ is hygroscopic and oxidation-prone; without careful handling, batches can degrade rapidly. Reproducible research with NAD+ in cell-culture or animal models requires confirmed identity, verified purity, and documented storage history.

PeptivaLabs publishes a per-batch HPLC and mass-spectrometry COA for every NAD+ batch we sell, with explicit identity confirmation at the molecular-weight level. Every vial ships with an NFC-encoded blockchain authentication tag, issued through our independent third-party authentication partner Authentichain — so the on-chain record is verifiable independent of PeptivaLabs. For laboratories running mitochondrial-function assays, sirtuin-activity studies, or cellular-aging research where NAD+ supply is the dependent variable, that source-quality verification is the foundation of reproducible results.

Selected References

Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 2000.

Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends in Cell Biology, 2014.

Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science, 2015.

Yoshino J, Baur JA, Imai S. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism, 2018.

Yoshino M, Yoshino J, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021.

Mills KF et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism, 2016.

Fang EF et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction. Cell, 2014.

Chini CCS, Tarragó MG, Chini EN. NAD and the aging process: Role in life, death and everything in between. Molecular and Cellular Endocrinology, 2017.

Camacho-Pereira J et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 2016.

Brakedal B et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metabolism, 2022.

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell, 2013.